Hepion Pharmaceuticals, Inc.
(NASDAQ : HEPA)

( )
HEPA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MYOKMyoKardia, Inc. -0.02%222.401.8%$502.40m
HZNPHorizon Therapeutics Plc -0.05%74.275.8%$155.39m
VRXValeant Pharmaceuticals International, Inc. 3.29%17.5814.1%$103.44m
CTLTCatalent, Inc. -0.79%92.422.1%$84.83m
JAZZJazz Pharmaceuticals Plc -2.04%145.392.4%$82.09m
BHCBausch Health Cos., Inc. 3.29%17.580.0%$68.73m
ICLRICON plc -0.54%202.234.3%$48.88m
UTHRUnited Therapeutics Corp. -0.27%118.8514.1%$44.28m
ZGNXZogenix, Inc. 1.54%20.507.5%$42.04m
SAGESAGE Therapeutics, Inc. -4.03%67.258.6%$41.83m
ARGXargenx SE -2.19%256.800.0%$38.95m
ENDPEndo International Plc -5.69%5.478.7%$36.31m
AMRNAmarin Corp. Plc -3.28%4.721.5%$35.22m
PRGOPerrigo Co. Plc -2.82%44.866.8%$32.47m
GWPHGW Pharmaceuticals Plc 0.56%96.896.2%$29.96m

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.